Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 12/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388657 | 0.79 | MEN1 (0.45) | TMEM97SIGMAR1NPC1RAB9ACXCR3 | |
| SCHEMBL29035758 | 0.78 | POLB (0.54) | — | |
| SCHEMBL8057168 | 0.76 | CCKBR (0.60) | RAB9AL3MBTL1 | |
| SCHEMBL8067607 | 0.75 | CCKBR (0.61) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL17736 | 0.74 | MEN1 (0.49) | TMEM97SIGMAR1NPC1RAB9AL3MBTL1 | |
| SCHEMBL21876840 | 0.74 | MEN1 (0.49) | TMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL25180666 | 0.73 | MEN1 (0.53) | TMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL10316948 | 0.73 | MEN1 (0.53) | TMEM97SIGMAR1NPC1RAB9A | |
| SCHEMBL8057095 | 0.73 | MAPT (0.47) | — | |
| SCHEMBL5966758 | 0.73 | CCKBR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6057311-A | TREATING EATING DISORDERS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| WO-1997032860-A1 | BENZODIAZONINE DERIVATIVES BINDING TO CHOLECYSTOKININ OR GASTRIN RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |